MOVE-OI: Evaluation of the Benefits of Adaptive Physical Activity in Children and Adolescents With Osteogenesis Imperfecta

Sponsor
Hospices Civils de Lyon (Other)
Overall Status
Recruiting
CT.gov ID
NCT04119388
Collaborator
(none)
30
1
1
35.9
0.8

Study Details

Study Description

Brief Summary

Osteogenesis imperfecta (OI) is a rare genetic disorder of increased bone fragility and low bone mass. It is conceivable that children and adolescents with OI are less active than healthy peers because of frequent fractures, immobilization,functionals limitations and no adapted physicals activity(APA). The hypothesis is that an Adapted physique activity could improve access of activity for patients with Osteogenesis Imperfecta (OI).

The aim of the study is to evaluate benefice of APA,improve aerobic capacity, cardiovascular and bone benefits, and gain of quality of life.

Children with OI between 6 and 18 years old will have a program of supervised "adapted training program" during one year. The program is adapted at each individual and without risk for the patient.

Condition or Disease Intervention/Treatment Phase
  • Other: Adapted sports practices
N/A

Study Design

Study Type:
Interventional
Anticipated Enrollment :
30 participants
Allocation:
N/A
Intervention Model:
Single Group Assignment
Masking:
None (Open Label)
Primary Purpose:
Prevention
Official Title:
Evaluation of the Benefits of Adaptive Physical Activity in Children and Adolescents With Osteogenesis Imperfecta
Actual Study Start Date :
Nov 4, 2019
Anticipated Primary Completion Date :
Nov 1, 2022
Anticipated Study Completion Date :
Nov 1, 2022

Arms and Interventions

Arm Intervention/Treatment
Experimental: Adapted sports practice

patients with osteogenesis imperfect will practice adapted sport twice a week during 12 months in order to improve their aerobic capacity, cardiovascular and bone benefits, and gain of quality of life.

Other: Adapted sports practices
Adapted sports practices for 30 minutes twice a week

Outcome Measures

Primary Outcome Measures

  1. 6 minutes walk test [Month 0]

    Distance traveled (in meters) in 6 minutes

  2. 6 minutes walk test [Month 6]

    Distance traveled (in meters) in 6 minutes

  3. 6 minutes walk test [Month 12]

    Distance traveled (in meters) in 6 minutes

Secondary Outcome Measures

  1. Weight [Month 0]

    weight in kilograms will be measured with a scale

  2. Weight [Month 6]

    weight in kilograms will be measured with a scale

  3. Weight [Month 12]

    weight in kilograms will be measured with a scale

  4. Height [Month 0]

    Size in meter measured with a meter

  5. Height [Month 6]

    Size in meter measured with a meter

  6. Height [Month 12]

    Size in meter measured with a meter

  7. body mass index [Month 0]

    calculated with weight and height

  8. body mass index [Month 6]

    calculated with weight and height

  9. body mass index [Month 12]

    calculated with weight and height

  10. blood pressure [Month 0]

    measurement of blood pressure (cm Hg)

  11. blood pressure [Month 6]

    measurement of blood pressure (cm Hg)

  12. blood pressure [Month 12]

    measurement of blood pressure (cm Hg)

  13. phosphocalcic biologic parameters [Month 0 and Month 12]

    Ionosodium (mmol/L)

  14. phosphocalcic biologic parameters [Month 0 and Month 12]

    potassium (mmol/L)

  15. phosphocalcic biologic parameters [Month 0 and Month 12]

    calcium (mmol/L)

  16. phosphocalcic biologic parameters [Month 0 and Month 12]

    chlore (mmol/L)

  17. phosphocalcic biologic parameters [Month 0 and Month 12]

    bicarbonates (mmol/L)

  18. phosphocalcic biologic parameters [Month 0 and Month 12]

    glucose (mmol/L)

  19. phosphocalcic biologic parameters [Month 0 and Month 12]

    urea (mmol/L)

  20. phosphocalcic biologic parameters [Month 0 and Month 12]

    creatinemia (mmol/L)

  21. phosphocalcic biologic parameters [Month 0 and Month 12]

    phosphorus (mmol/L)

  22. phosphocalcic biologic parameters [Month 0 and Month 12]

    proteinemia (g/L)

  23. phosphocalcic biologic parameters [Month 0 and Month 12]

    Vitamin D (nmol/L)

  24. phosphocalcic biologic parameters [Month 0 and Month 12]

    1-25 OH vitamin D (pmol/L)

  25. phosphocalcic biologic parameters [Month 0 and Month 12]

    PTH (ng/L)

  26. phosphocalcic biologic parameters [Month 0 and Month 12]

    alkaline bone phosphatases (U/L)

  27. phosphocalcic biologic parameters [Month 0 and Month 12]

    CTX (pg/ml)crosslaps

  28. phosphocalcic biologic parameters [Month 0 and Month 12]

    osteocalcin (µg/L)

  29. phosphocalcic biologic parameters [Month 0 and Month 12]

    ferritin (µg/L)

  30. phosphocalcic biologic parameters [Month 0 and Month 12]

    blood count formula : leucocytes (giga/L), erythrocytes (tera/L), hemoglobin (g/L), hematocrit (%), platelets (giga/L)

  31. phosphocalcic biologic parameters [Month 0 and Month 12]

    calciuria (mmol/L)

  32. phosphocalcic biologic parameters [Month 0 and Month 12]

    Ionosodium (mmol/L) potassium (mmol/L), calcium (mmol/L), chlore (mmol/L), bicarbonates (mmol/L), glucose (mmol/L), urea (mmol/L), creatinemia (mmol/L), phosphorus (mmol/L), proteinemia (g/L), Vitamin D (nmol/L), 1-25 OH vitamin D (pmol/L), PTH (ng/L), alkaline bone phosphatases (U/L), CTX (pg/ml)crosslaps, osteocalcin (µg/L), NFS, ferritin (µg/L), blood count formula : leucocytes (giga/L), erythrocytes (tera/L), hemoglobin (g/L), hematocrit (%), platelets (giga/L), calciuria (mmol/L), urinary creatinin (mmol/L).

  33. ration lean mass / fat mass [Month 0]

    Dual-energy X-ray absorptiometry (DXA)

  34. ration lean mass / fat mass [Month 12]

    Dual-energy X-ray absorptiometry (DXA)

  35. Respiratory Functional Exploration [Month 0]

  36. Respiratory Functional Exploration [Month 12]

  37. Thickness intima / media [Month 0]

    echography

  38. Parameters of the connected watch : number of steps [Month 0 and Month 6 and Month 12]

    data recovery of the connected watch

  39. Parameters of the connected watch : distance traveled [Month 0 and Month 6 and Month 12]

    data recovery of the connected watch

  40. Parameters of the connected watch : calories consumption [Month 0 and Month 6 and Month 12]

    data recovery of the connected watch

  41. Ratio thickness intima / media [Month 12]

    echography

  42. Bone mineral density [Month 0]

    Dual-energy X-ray absorptiometry (DXA)

  43. Bone mineral density [Month 12]

    Dual-energy X-ray absorptiometry (DXA)

  44. Number of new fractures [Month 1]

  45. Number of new fractures [Month 3]

  46. Number of new fractures [Month 6]

  47. Number of new fractures [Month 9]

  48. Number of new fractures [Month 12]

  49. Quality of life questionnaire : PedsQL [Month 0]

    Measurement Model for the Pedratric Quality of Life Inventory The 4 Multidimensional Scales and 3 Summary Scores are Scales Physical Functioning (8 items) Emotional Functioning (5 items) Social Functioning (5 items) School Functioning (5 items) Summary Scores Total Scale Score (23 items) Physical Health Summary Score (8 items) Psychosocial Health Summary Score (15 items)

  50. Quality of life questionnaire : PedsQL [Month 6]

    Measurement Model for the Pedratric Quality of Life Inventory The 4 Multidimensional Scales and 3 Summary Scores are Scales Physical Functioning (8 items) Emotional Functioning (5 items) Social Functioning (5 items) School Functioning (5 items) Summary Scores Total Scale Score (23 items) Physical Health Summary Score (8 items) Psychosocial Health Summary Score (15 items)

  51. Quality of life questionnaire : PedsQL [Month 12]

    Measurement Model for the Pedratric Quality of Life Inventory The 4 Multidimensional Scales and 3 Summary Scores are Scales Physical Functioning (8 items) Emotional Functioning (5 items) Social Functioning (5 items) School Functioning (5 items) Summary Scores Total Scale Score (23 items) Physical Health Summary Score (8 items) Psychosocial Health Summary Score (15 items)

Eligibility Criteria

Criteria

Ages Eligible for Study:
6 Years to 17 Years
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
No
Inclusion Criteria:
  • Child with osteogenesis imperfecta

  • Child followed in the Reference centre for constitutional bone diseases in the Hôpital Femme Mère Enfant

  • Parent (s) / legal guardian who has been informed of the study and has accepted participation in the study by signing the consent.

  • Patient benefiting from a social security scheme

Exclusion Criteria:
  • Medical and surgical contraindications to adapted physical activity.

Contacts and Locations

Locations

Site City State Country Postal Code
1 Centre de Référence des Maladies Rénales Rares - Hospices Civils de Lyon - Service de Néphrologie et Rhumatologie Pédiatriques - Hôpital Femme Mère Enfant Bron France 69500

Sponsors and Collaborators

  • Hospices Civils de Lyon

Investigators

None specified.

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
Hospices Civils de Lyon
ClinicalTrials.gov Identifier:
NCT04119388
Other Study ID Numbers:
  • 69HCL18_0747
  • ID-RCB
First Posted:
Oct 8, 2019
Last Update Posted:
Nov 20, 2020
Last Verified:
Nov 1, 2020
Individual Participant Data (IPD) Sharing Statement:
Undecided
Plan to Share IPD:
Undecided
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Keywords provided by Hospices Civils de Lyon
Additional relevant MeSH terms:

Study Results

No Results Posted as of Nov 20, 2020